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Abstract: To evaluate the value of a breast computed tomography (CT) (B-CT) in assessing breast
density, pathologies and implant integrity in women with breast implants.This retrospective study was
approved by the local ethics committee. B-CT images of 21 women with implants (silicone/saline;
20 bilateral, 1 unilateral) who underwent opportunistic screening or diagnostic bilateral B-CT were
included. Breast density, implant integrity, extensive capsular fibrosis, soft tissue lesions and micro-
/macrocalcifications were rated. In 18 of the 21 women, an additional ultrasound and in two patients
breast magnetic resonance imaging was available for comparison. The average dose was calculated for
each breast using verified Monte Carlo simulations on 3D image data sets.Breast density was nearly
completely fatty (ACR a) in two patients, scattered fibroglandular (ACR b) in five, heterogeneously
dense (ACR c) in ten and very dense (ACR d) in four women. In three women showed a unilateral
positive Linguine sign indicative of an inner capsule rupture. Extensive capsular fibrosis was found in
three women. In three women, soft tissue lesions were depicted, which revealed to be cysts (n = 2) and
lymph nodes (n = 1) on subsequent sonography. Diffuse, non-clustered microcalcifications were found
in nine women. Eleven women showed cutaneous or intramammary macrocalcifications. Average dose
was 6.45 mGy (range 5.81-7.28 mGy).In women with implants, B-CT presents a promising modality for
evaluating breast density, implant integrity, extensive capsular fibrosis, soft tissue lesions and micro-
/macrocalcifications without the need of breast compression utilizing a lower dose compared to doses
reported for conventional four-view mammography.
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Abstract
To evaluate the value of a breast computed tomography (CT) (B-CT) in assessing breast density, pathologies and implant integrity in
women with breast implants.
This retrospective study was approved by the local ethics committee. B-CT images of 21 women with implants (silicone/saline; 20
bilateral, 1 unilateral) who underwent opportunistic screening or diagnostic bilateral B-CT were included. Breast density, implant
integrity, extensive capsular fibrosis, soft tissue lesions and micro-/macrocalcifications were rated. In 18 of the 21 women, an
additional ultrasound and in two patients breast magnetic resonance imaging was available for comparison. The average dose was
calculated for each breast using verified Monte Carlo simulations on 3D image data sets.
Breast density was nearly completely fatty (ACR a) in two patients, scattered fibroglandular (ACR b) in five, heterogeneously dense
(ACR c) in ten and very dense (ACR d) in four women. In three women showed a unilateral positive Linguine sign indicative of an
inner capsule rupture. Extensive capsular fibrosis was found in three women. In three women, soft tissue lesions were depicted,
which revealed to be cysts (n=2) and lymph nodes (n=1) on subsequent sonography. Diffuse, non-clustered microcalcifications
were found in nine women. Eleven women showed cutaneous or intramammary macrocalcifications. Average dose was 6.45 mGy
(range 5.81–7.28 mGy).
In women with implants, B-CT presents a promising modality for evaluating breast density, implant integrity, extensive capsular
fibrosis, soft tissue lesions andmicro-/macrocalcifications without the need of breast compression utilizing a lower dose compared to
doses reported for conventional four-view mammography.
Abbreviations: ABUS = automated breast ultrasound, B-CT = breast computed tomography, CT = computed tomography, MC
= Monte Carlo, MRI = magnetic resonance imaging.
Keywords: breast, breast implants, breast neoplasms, spiral computed tomography
1. Introduction
In 2018, 313.735 women and teenagers underwent breast
augmentation surgery using silicone (88%) or saline (12%)
implants and 29.236 women had breast implants removed in the
United States.[1] Implants come alongwith a number of problems,
such as implant rupture,[2] capsular contracture as well as
difficult breast cancer screening and diagnosis,[3,4] which can be
challenging for radiologists.
Four-view mammography presents the current reference
standard for breast cancer screening in women with implants
according to the guidelines of the American Cancer Society
(ACS).[5,6] Augmentation mammography comes with the
disadvantage of a higher mean glandular dose due to decreased
compression as well as radiation absorption of the implant
itself.[7,8] The discomfort caused by compression during
mammography can be particularly enhanced in women
with implants. Mammography cannot, in most of the cases,
detect intracapsular ruptures, which account for the majority
of mplant failures.[9] In addition, although very rare,
mechanical pressure during mammography can lead to implant
rupture.[10]
Editor: Oguzhan Ekizoglu.
The authors have no funding and no conflicts of interest to disclose.
The datasets generated during and/or analyzed during the current study are not
publicly available, but are available from the corresponding author on reasonable
request.
Institute of Diagnostic and Interventional Radiology, University Hospital Zurich,
Rämistrasse, Zürich, Switzerland.
∗
Correspondence: Lisa Ruby, Institute of Diagnostic and Interventional
Radiology, University Hospital Zurich, Rämistrasse 100, 8091 Zürich, Switzerland
(e-mail: lisa.ruby@usz.ch).
Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc.
This is an open access article distributed under the terms of the Creative
Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is
permissible to download, share, remix, transform, and buildup the work provided
it is properly cited. The work cannot be used commercially without permission
from the journal.
How to cite this article: Ruby L, Shim S, Berger N, Marcon M, Frauenfelder T,
Boss A. Diagnostic value of a spiral breast computed tomography system
equipped with photon counting detector technology in patients with implants: An
observational study of our initial experiences. Medicine 2020;99:30(e20797).







Ultrasound presents a moderately goodmodality in augmented
breasts as implant integrity can be assessed,[11] but it is not
sufficient for breast cancer screening as a stand-alone method.[12]
Magnetic resonance imaging (MRI) is the most accurate
modality for the evaluation of implant integrity in women with
implants.[13–16] The United States Food and Drug Administration
recommends a primary MRI screening three years after implant
insertion and every two years afterwards to detect silicone
rupture.[17] However, the high costs, multiple contraindications
(metals, claustrophobia) as well as the inability to detect or
characterize calcifications that come with MRI have led to a
demand for an additional modality in women with implants.
Currently, there are not specific recommendations to use breast
MRI for breast cancer screening purpose in women with implants.
Therefore, there is a demand for a modality, which can
combine the advantages of both mammography and MRI in
terms of calcification detection and implant integrity assessment.
Spiral breast computed tomography (CT) (B-CT) with a photon-
counting detector offers a fast examination, providing high-
quality images without the need of compression or contrast agent
application.[18] Berger and Marcon et al. have demonstrated the
capability of the B-CT to detect soft tissue lesions as well as
micro- and macrocalcifications, serving as an alternative method
for conventional mammography, especially in those patients not
willing to undergo a mammography exam because of breast
compression.[18,19] However, the value of this new technology in
assessing implant integrity, breast density and pathologies has
not been evaluated for patients with implants in the literature.
The purpose of this study was to investigate the potential of a
spiral B-CT in evaluating breast density, implant integrity,
extensive capsular fibrosis, soft tissue lesions as well as micro-
and macrocalcifications in breasts augmented by implants.
2. Methods
All breast CTs performed at our institute in the timeframe 01/
2018–09/2019 were analyzed retrospectively. The study was
approved by the local ethics committee (Kantonale Ethikkom-
mission Zürich; approval number: 2016–00064). Written
informed consent was obtained from all women. B-CT
examinations were performed in women with breast implants
undergoing opportunistic breast cancer screening, in patients
with a history of breast cancer or in symptomatic patients
(mastodynia, palpation findings). Breast CT was offered as an
alternative modality for patients refusing the indicated mam-
mography or MRI exam due to inherent breast compression or
contrast agent application. For all symptomatic patients, women
with a finding or dense breast tissue on breast CT, a supplemental
ultrasound examination of both breasts was performed either
using a handheld ultrasound system (Philips iU22A, Philips or
Logiq E9, GE Healthcare) or automated breast ultrasound
(Invenia ABUS, GE Healthcare).
2.1. Breast-CT (B-CT)
All women were placed in prone position in a spiral breast CT
(nu:view; AB-CT [Advanced Breast CT] GmbH). Each breast was
examined separately starting with the left side. The detector is
equipped with telluride crystals and the detector area has a total
size of 280500mm. A fixed x-ray tube voltage of 60kV and a
tube current of 32mAswere used for all patients (at the beginning
breast CT examinations at our institution were performed with
25mAs, later changing the settings to 32mAs for better depiction
of microcalcifications). All examinations were performed with
the nu:view reconstruction software, which utilizes a Feldkamp-
type filtered back-projection algorithm for image reconstruc-
tions. A voxel size of 300mm3 and 4  4 detector binning were
used for the standard image reconstruction, whereas a kernel of
150mm3 voxel size with 22 detector binning was used for a
high-resolution image reconstruction. Images were reconstructed
to a size of 0.3mm for the standard and 0.15mm for the high-
resolution images. The images were analyzed on a picture
archiving and communication system workstation equipped with
a customized breast imaging display software (AGFA Impax 6),
enabling sagittal and coronal reformations as well as maximum
intensity projections (MIP).
2.2. Reading and statistical evaluation
Using the report by the reporting radiology resident confirmed by
an experienced radiologist (experience >15 years), the images
were additionally descriptively analyzed by a second-year
radiology resident. Breast density was visually assessed for each
patient; lobular involution was defined as <25% parenchyma,
fibroglandular-scattered as 25% to 50% parenchyma, heteroge-
neously dense as 51% to 75% parenchyma, extremely dense as
>75% parenchyma.[20] Images were analyzed regarding the
presence of the following features: implant location (epipectoral/
subpectoral), intra-/extracapsular implant rupture, extensive
capsular fibrosis (defined as soft-tissue-isodense material with
calcifications surrounding the implant), soft tissue lesions and
micro-/macrocalcifications.
2.3. Dose calculation
Radiation dose was calculated byMonte Carlo (MC) simulations
using a commercially available validated tool.[21–23] 1.0E6
photon histories were simulated for each MC calculation. The
results of the MC simulations were normalized by the air kerma
of 18.12 mGy per 100 mAs. The average dose of each breast was




21 women (median age 50.5 years, range 35–72 years) with
breast implants (silicone or saline; 20 bilateral, 1 unilateral) who
underwent bilateral B-CTwere included in the study. The woman
with a unilateral implant had a history of multi-centric, invasive
ductal breast cancer in the right breast, which was treated with
segmentectomy and radiation therapy. Apart from this patient,
none of the included women had a history of breast cancer. 5/21
(23.8%) had a first or second degree relative with breast cancer,
16/21 did not have a first or second degree relative with breast
cancer. For 18/21 women (85.7%), an additional ultrasound
examination was performed on the day of the B-CT examination
(15 handheld ultrasound, 3 ABUS). For two women (9.5%),
previous MRI exams were available.
3.2. Breast density
2/21 (10%) breasts showed (complete) lobular involution (Fig. 1A),
5/21 (24%) were fibroglandular scattered (Fig. 1B), 10/21 (48%)
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were heterogeneously dense (Fig. 1C), whereas 4/21 (19%) were
extremely dense (Fig. 1D). In the fibroglandular dense type,
glandular tissue adapted to the form of the implant showing a
parallel alignment to the implant borders (arrows in Fig. 1B),
whereas for the other three density types no such patternwas found.
3.3. Breast implants
For 7/21 patients, implants were located subpectorally, whereas
for 14/21 patients, implants were located epipectorally. Silicone
exhibited a notably higher density corresponding to higher X-ray
attenuation compared to glandular tissue and fat. Intermediate
density was observed for the plastic material of the implant
coating. Nearly identical density was found for glandular tissue
and the pectoral muscle.
In 3/21 (14%) women, a unilateral implant rupture was
detected. Fig. 2 demonstrates breast CT images and correspond-
ing automated breast ultrasound (ABUS) images of a 35-year old
woman with a first degree family history of breast cancer and
bilateral implants for six years, who rejected anMRI exam due to
the associated contrast agent application. Both modalities
revealed implant folds in the left breast (Figs. 2A and C) and a
positive Linguine sign in the right breast (Figs. 2B and D),
indicative of an intracapsular rupture.
Extensive capsular fibrosis was detected in 3/21 (14%) women.
Fig. 3 displays severe calcifications in a 62-year old womanwith a
Figure 1. A-D. Coronal view of B-CT images. The figure displays the implant embedded in breasts of different density, showing A) lobular involution, B)
fibroglandular-scattered, C) heterogeneously dense and D) extremely dense tissue.
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history of bilateral implants for 46 years, who presented to our
clinic with severe discomfort due to bilateral breast induration.
3.4. Breast lesions
Intramammary soft tissue lesions were found in 3/21 (14%)
women, two revealed to be simple cysts and the third an
intramammary lymph node. Fig. 4 shows an intramammary
lesion in a 48-year old, asymptomatic woman with a six-year
history of bilateral implants who presented for routine breast
cancer screening. B-CT displayed a 10 x 6mm measuring, oval
soft tissue mass at 1–2 o’clock (Fig. 4A). A subsequent ultrasound
examination (Fig. 4B) depicted a sharply aligned, anechoic lesion
with dorsal acoustic enhancement, which was interpreted as a
simple cyst.
Microcalcifications were found in 9/21 (43%), macrocalcifi-
cations or cutaneous calcifications in 11/21 (52%) of the included
patients. No clustered or otherwise suspicious microcalcifications
were found. Exemplary typical intramammary micro- (Fig. 5A
and C) and macrocalcifications (Figs. 5B and D) after several
implant revision surgeries are shown in a 65-year old woman.
3.5. Intermodality comparison B-CT vs. MRI
Previously acquired MRI images were available for 2/21 (10%)
women. To illustrate the comparison between B-CT and MRI
(MRI images were acquired 2 years prior to the B-CT
examination), the images of a 35-year old woman with a family
history of breast cancer who presented to our clinic for a
screening examination are shown in Fig. 6. From the example
images, it can be seen that the B-CT images exhibit features of
both, T1-weighted and silicone–selective T2-weighted images
with clear depiction of breast parenchyma and high density of the
implants. In the MRI silicone-selective sequence, no parenchymal
Figure 2. A-D. A 35-year old woman presenting with a family history of breast cancer (mother who was diagnosed with breast cancer at the age of 40 yrs) and
bilateral gel implants for six yrs. Breast CT revealed implant folds in the left breast (A) and a positive Linguine sign in the right breast (B), indicative of an intracapsular
rupture (coronal views, respectively). Automated breast ultrasound (ABUS) confirmed the observed findings for the left (C) and right (D) breasts.
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tissue is depicted, whereas in the T1-weighted image, the silicone
implant shows low signal intensity.
3.6. Average dose
Including all B-CTmeasurements for the 21 women, we found an
average dose of 6.45 mGy (SD 0.36; range 5.81–7.28 mGy)
(Table 1). For the patient with a unilateral implant (patient 15),
we calculated a dose of 6.21 mGy (SD 0.12 mGy) for the right
(implant) breast and 6.15 mGy (SD 0.12 mGy) for the left (non-
implant) breast.
4. Discussion
Our results demonstrate the potential clinical value of a spiral B-
CT in evaluating breast density, implant integrity, extensive
capsular fibrosis, intramammary soft tissue lesions as well as
micro- and macrocalcifications in women with breast implants
without the need of contrast agent application or painful breast
compression. It is the only modality providing both, excellent
depiction of implants and microcalcifications in a single
examination without overlay effects.
MRI of the breast presents the most accurate method to assess
implant integrity.[13–16] However, the high costs and multiple
contraindications (metals, claustrophobia) that come with MRI
have led to a demand for an additional modality in women with
implants. Furthermore, assessment of microcalcifications is
hardly possible in MRI,[24–26] which is particularly important
for the diagnosis of breast cancer precursors and lesions of
unknown malignant potential (B3 lesions).
Mammography, which presents the screening method of
choice for women with implants in some countries,[5,6] comes
with the disadvantage of a higher mean glandular dose in
augmented breasts due to decreased compression as well as
radiation absorption of the implant itself.[7,8] Recommended
four-view augmentation mammography is associated with a
more than threefold mean glandular dose (10.7 mGy) compared
to conventional two-view mammography (3.4 mGy).[8] For the
Figure 4. A, B. A 48-yr old, asymptomatic woman with a history of bilateral gel implants for six yrs presented for routine breast cancer screening. The displayed
coronal B-CT image (A) shows a 10 x 6mmmeasuring, oval consolidation at 1-2 o’clock. A subsequent sonographic exam (B) showed a sharply aligned, anechoic
lesion with dorsal acoustic enhancement, which was interpreted as a simple cyst.
Figure 3. A, B. A 62-yr old woman with bilateral breast implants for 46 yrs. She presented to our clinic with bilateral breast induration. Severe calcifications
surrounding the implant can be seen bilaterally in the coronal breast CT images on the left A) and right B) side.
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breast CT, we found an average dose of 6.45mGy (SD 0,36; range
5.81 7.28 mGy) in women with implants. In comparison, Berger
and Marcon et al. calculated a dose of 5.08 mGy (range 4.4–5.7
mGy) in a screening population without implants using the same
spiral breastCTsystem.[19]Although, to the best ofourknowledge,
no recent clinical studies have proven an inferior diagnostic
performanceofmammography inwomenwith implants compared
to women without implants, in a MC simulation study it has been
shown that silicone gel implants thicker than 26mm for the case of
mammography and 14 mm for the case of B-CT obscured the
visibility of underlying structures, such as soft tissue masses and
microcalcifications.[27] In B-CT, due to the possibility to obtain
cross-sectional images rather than projection images as in
mammography, not only the superimposition of the implant but
also of the glandular tissue can be reduced.
According to Berger and Marcon et al., B-CT provides similar
information with regard to soft tissue lesion detection without
superimposition compared to mammography.[18,19] In line with
this, we were able to detect intramammary soft tissue lesions in
patients with implants. Features, such as density (Hounsfield
units), shape and margins, help in the differentiation of the
lesions. However, similar to mammography, the potential in
differentiating structures of similar density, such as very dense
breast tissue and soft tissue lesions, but alsomild fibrosis andmild
peri-implant fluid, is limited. Therefore, ultrasound remains an
indispensable, complementary method for the further classifica-
tion of lesions detected on mammography or CT, in symptomatic
women, women with dense breasts and for the assessment of
implant integrity.[11,28,29] Although ultrasound has undergone
remarkable improvement in recent years with increased resolu-
tion and the utilization of additional parameters, such as elastic
modules, it is by itself not sufficient for breast cancer screening
and diagnosis as a stand-alone method due to its decreased
sensitivity in detecting DCIS and small tumors in breasts
characterized by shadowing and fibrocystic changes.[29–31] B-
CT covers these limitations. Moreover, ultrasound is a very
examiner-dependent modality,[29] whereas for the B-CT, images
are acquired in a reproducible way and can be analyzed by a
second radiologist at a later time point. Regarding the radiation
exposure that comes with the B-CT in contrast to ultrasound, the
benefits of mammographic screening with a remarkable mortality
reduction have been shown to outweigh the comparably small
risk of radiation-induced cancer and should therefore not prevent
women above the age of 40 from undergoing screening
mammography or the alternative B-CT,[32–34]which is associated
with a comparable dose compared to mammography.[18,19,35]
We want to point out that we do not regard breast-CT and
ultrasound as competing modalities but rather as modalities
complementing each other.
Considering the costs of both, B-CT and ultrasound, as with
any novel technique with only a few devices available worldwide,
purchase costs of the B-CT are high compared to ultrasound
devices. However, a decrease in costs over time can be expected
with a widespread use of this method and competing vendors. At
our institute, B-CT examination costs are equivalent to that of
mammography (CHF 193) and slightly higher compared to
ultrasound (CHF 165).
Examination and interpretation times of mammography and
B-CT are very short (5minutes) for both breasts, whereas
examination times of a thorough ultrasound exam performed by
a radiologist range between 25 and 30 minutes,[36] which also
results in higher costs.
The potential of dual-energy CT in the assessment of implant
integrity has been shown in the literature.[37,38] The linguine
sign,[13] which represents the collapsed implant shell in the gel
showing a high sensitivity and specificity for an intracapsular
rupture,[39] was identified with the B-CT, in spite of the single
energy spectrum applied.
Figure 5. A-D. Single micro- (A,C) and macrocalcifications (B, D) are displayed in the axial (A,B) and sagittal (C,D) plane in a 65-yr old woman with bilateral gel
implants, which required several revision surgeries.
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Limitations of our study include the missing direct comparison
with MRI or mammography regarding the detection of
pathologies and comparison of dose (B-CT vs. mammography).
Further limitations are the low number of women with implants
in the given study period, the lack of patients with breast cancer
diagnosis and implants, the missing follow-up examinations as
well as the retrospective study design. However, our initial
experiences demonstrate a great potential of this novel B-CT
technique in evaluating augmented breasts, which might become
the modality of choice for fast and time-efficient breast imaging in
patients with implants.
Giving an outlook, further steps, which aim at improving the
differentiation of lesions, might include the application of iodine
contrast agents.[40] Moreover, as a further technical milestone,
phase contrast B-CT might strongly improve the specificity of
microcalcification assessment.[41,42]
In conclusion, B-CT presents a promising modality for implant
integrity assessment and breast cancer screening in women with
implants without a need of breast compression, utilizing a lower
dose compared to reported doses for conventional four-view
mammography.
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